Showing papers by "Vicente Estrada published in 2009"
TL;DR: Suboptimal adherence, lower baseline haemoglobin and a nadir CD4(+) T-cell count <100 cells/microl were the main risk factors for losing virological suppression in patients randomized to monotherapy with LPV/r.
Abstract: BackgroundRisk factors for loss of virological response in patients receiving lopinavir/ritonavir (LPV/r) monotherapy as maintenance treatment have not been determined.MethodsIn 121 patients enroll...
65 citations
TL;DR: Prevalence of smoking in patients with HIV infection is double that of the general population and smoking is the modifiable cardiovascular risk factor that contributes most to causing premature CV disease.
Abstract: Background
Smoking is the modifiable cardiovascular (CV) risk factor that contributes most to causing premature CV disease. Prevalence of smoking in patients with HIV infection is double that of the general population.
Objectives
To determine the rate of patients succeeding in quitting smoking after 12 months, factors associated with this success, and the characteristics of tobacco consumption and nicotine dependence.
Methods
Longitudinal descriptive study. Three hundred and sixty-eight HIV-infected patients were interviewed. Smokers in Prochaska's stage of action began a programme to quit smoking. We registered the variables related to tobacco consumption and the level of success of cessation.
Results
63.9% of the patients were active smokers and 14% of them began the cessation programme. Average motivation for cessation was 7.8 ± 1.4 (Richmond) and nicotine dependence rate 5.5 ± 3.0 (Fagerstrom). After 1 year, 25% had quit smoking. Those patients who stopped smoking presented a higher motivation level (8.8 ± 1.3 vs. 7.5 ± 1.5, P=0.048). Cessation significantly reduced their CV risk at 12 months {2.5 [interquartile range (IQR) 2.0–5.2] vs. 1.7 [IQR 1.0–3.5], P=0.026}.
Conclusions
The prevalence of smokers in our population of HIV-infected patients was 63.9%. Only 14% began a smoking cessation programme. Twelve months after a programme to quit smoking, cessation rate was 25%; this was influenced mostly by the level of motivation of the patient.
55 citations
TL;DR: The findings of the KLEAN study extension support durable viral suppression with both FPV/r and LPV/ r treatment regimens when used in combination with ABC/3TC irrespective of viral load at baseline.
Abstract: Purpose: The KLEAN study extension assessed the long-term efficacy and safety of fosamprenavir-ritonavir (FPV/r) and lopinavir-ritonavir (LPV/r), both administered with abacavir/lamivudine (ABC/3TC) fixed dose combination, over 144 weeks Methods: KLEAN was an open-label, noninferiority study that randomised antiretroviral-naive patients to FPV/r twice daily (bid) or LPV/r bid with ABC/3TC once daily (qd) Patients with a viral load of 100,000 or ⩽100,000 copies/mL) The Week 144 median (interquartile range) change from baseline CD4+ cel
29 citations